AU591466B2
(en)
*
|
1984-10-22 |
1989-12-07 |
Vestar, Inc. |
Method of delivering micellular particles encapsulating imaging and chemotherapeutic agents to tumors in a body
|
DE3510795A1
(de)
*
|
1985-03-25 |
1986-09-25 |
Udo Dr.med. 8400 Regensburg Ehrenfeld |
Mikrobieller extrakt (jomol), seine herstellung und seine verwendung als diagnostikum und arzneimittel. derivate des jomol
|
EP0221821A3
(de)
*
|
1985-11-01 |
1988-01-27 |
Centre National De La Recherche Scientifique (Cnrs) |
Aerosolzusammensetzung für in-vivo-Abbildung und Therapie
|
JPS63107742A
(ja)
*
|
1986-05-20 |
1988-05-12 |
Wako Pure Chem Ind Ltd |
新規な機能性リポソ−ム及びその製造法
|
DE3621570A1
(de)
*
|
1986-06-27 |
1988-01-07 |
Hoechst Ag |
Diagnostikum zur szintigraphischen darstellung von boesartigen tumoren
|
ATE87215T1
(de)
*
|
1987-07-21 |
1993-04-15 |
Stolle Res & Dev |
Verfahren zum erhalten von immunregulierenden faktoren mittels saeugetierimmunisierung.
|
FR2644059B1
(fr)
*
|
1989-03-08 |
1994-03-04 |
Fabre Medicament Pierre |
Compositions aerosols destinees a l'imagerie, au diagnostic et a la therapie ciblee de foyers inflammatoires et tumoraux
|
FR2655546B1
(fr)
*
|
1989-12-11 |
1992-03-13 |
Assistance Publique |
Composition pour injection intratumorale, et utilisation pour le marquage prechimiotherapique et preoperatoire, en laserotherapie et en thermotherapie.
|
US5620703A
(en)
*
|
1991-10-11 |
1997-04-15 |
Max-Delbruck-Centrum Fur Molekulare Medizin |
Stimulating hematopoietic activity with carboplatin or lobaplatin
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
US6649143B1
(en)
|
1994-07-01 |
2003-11-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-invasive localization of a light-emitting conjugate in a mammal
|
US5650135A
(en)
*
|
1994-07-01 |
1997-07-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-invasive localization of a light-emitting conjugate in a mammal
|
US7255851B2
(en)
|
1994-07-01 |
2007-08-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-invasive localization of a light-emitting conjugate in a mammal
|
US6093697A
(en)
*
|
1994-11-07 |
2000-07-25 |
The University Of Virginia Patent Foundation |
Synthetic insulin mimetic substances
|
US6190657B1
(en)
|
1995-06-07 |
2001-02-20 |
Yale University |
Vectors for the diagnosis and treatment of solid tumors including melanoma
|
EP1820517A3
(de)
*
|
1995-11-17 |
2009-10-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nichtinvasive Lokalisierung eines lichtemittierenden Konjugats bei einem Säugetier
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
ES2248823T5
(es)
|
1996-10-25 |
2011-11-03 |
Human Genome Sciences, Inc. |
Neutroquina alfa.
|
US6156728A
(en)
|
1996-11-01 |
2000-12-05 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
US6593290B1
(en)
|
1996-11-01 |
2003-07-15 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
EP1015477B1
(de)
|
1997-05-30 |
2010-11-10 |
Human Genome Sciences, Inc. |
32 Humane sekretierte Proteine
|
US6663899B2
(en)
|
1997-06-13 |
2003-12-16 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
US6113947A
(en)
*
|
1997-06-13 |
2000-09-05 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
EP1012232B1
(de)
*
|
1997-09-10 |
2009-10-28 |
Vion Pharmaceuticals, Inc. |
Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz
|
US6080849A
(en)
|
1997-09-10 |
2000-06-27 |
Vion Pharmaceuticals, Inc. |
Genetically modified tumor-targeted bacteria with reduced virulence
|
US6455283B1
(en)
|
1998-03-17 |
2002-09-24 |
Genentech, Inc. |
Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)
|
US5906979A
(en)
*
|
1998-01-27 |
1999-05-25 |
Insmed Pharmaceuticals, Inc. |
Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
|
ATE276756T1
(de)
|
1998-02-04 |
2004-10-15 |
Genentech Inc |
Verwendung des heregulins als epithelzellenwachstumsfaktor
|
EP2050762A3
(de)
|
1998-03-10 |
2009-07-08 |
Genentech, Inc. |
Neue Polypeptide und für diese kodierende Nukleinsäuren
|
EP1093457B8
(de)
|
1998-03-19 |
2011-02-02 |
Human Genome Sciences, Inc. |
Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
|
AUPP785098A0
(en)
|
1998-12-21 |
1999-01-21 |
Victor Chang Cardiac Research Institute, The |
Treatment of heart disease
|
EP2357192A1
(de)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
|
US6635249B1
(en)
|
1999-04-23 |
2003-10-21 |
Cenes Pharmaceuticals, Inc. |
Methods for treating congestive heart failure
|
US6962696B1
(en)
*
|
1999-10-04 |
2005-11-08 |
Vion Pharmaceuticals Inc. |
Compositions and methods for tumor-targeted delivery of effector molecules
|
EP1274720A4
(de)
|
2000-04-12 |
2004-08-18 |
Human Genome Sciences Inc |
Albumin enthaltende fusionsproteine
|
EP2431054A3
(de)
|
2000-06-15 |
2013-03-06 |
Human Genome Sciences, Inc. |
Menschlicher Tumornekrosefaktor Delta und Ypsilon
|
EP2042597B1
(de)
|
2000-06-23 |
2014-05-07 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
|
CA2648048A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
EP1572887A4
(de)
|
2001-08-24 |
2008-12-24 |
Neuren Pharmaceuticals Ltd |
Nervenregenerierungspeptid und verfahren zu deren verwendung bei der behandlung einer hirnschädigung
|
KR101008734B1
(ko)
|
2001-08-29 |
2011-01-14 |
제넨테크, 인크. |
유사분열촉진 활성을 가진 Bv8 핵산 및 폴리펩티드
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
DK1499277T3
(da)
|
2001-09-24 |
2009-05-11 |
Imp Innovations Ltd |
PYY-36 til reduktion eller forebyggelse af obesitet
|
CA2462883A1
(en)
|
2001-10-12 |
2003-04-17 |
Schering Corporation |
Use of bispecific antibodies to regulate immune responses
|
CA2841097A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin and g-csf fusion proteins
|
US8058233B2
(en)
*
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
WO2003057235A2
(en)
|
2002-01-10 |
2003-07-17 |
Imperial College Innovations Ltd |
Modification of feeding behavior
|
AU2002304965A1
(en)
|
2002-05-24 |
2003-12-12 |
Zensun (Shanghai) Sci-Tech.Ltd |
Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
|
EP2305710A3
(de)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetische Antikörperphagenbibliotheken
|
CN100434440C
(zh)
|
2002-12-02 |
2008-11-19 |
阿布格尼克斯公司 |
针对肿瘤坏死因子的抗体及其用途
|
GB0300571D0
(en)
*
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
EP2526960A1
(de)
|
2003-03-12 |
2012-11-28 |
Genentech, Inc. |
Verwendung von BV8 und/oder EG-VEGF zum Fördern der Hämatopoiese
|
EP1613750B1
(de)
|
2003-03-19 |
2015-10-14 |
Amgen Fremont Inc. |
Antikörper gegen das t-zellen-immunglobulindomäne- und mucindomäne-1 (tim-1) antigen und verwendungen davon
|
US7375076B2
(en)
|
2003-05-20 |
2008-05-20 |
The Regents Of The University Of Michigan |
Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
|
US7291590B2
(en)
|
2003-06-12 |
2007-11-06 |
Queen's University At Kingston |
Compositions and methods for treating atherosclerosis
|
CA2530285C
(en)
|
2003-06-27 |
2019-12-24 |
Abgenix, Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
US7258864B2
(en)
|
2003-09-12 |
2007-08-21 |
Tercica, Inc. |
Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency
|
AU2005209926B2
(en)
*
|
2004-02-02 |
2007-09-06 |
Ambrx, Inc. |
Modified human four helical bundle polypeptides and their uses
|
US20050260679A1
(en)
|
2004-03-19 |
2005-11-24 |
Sirid-Aimee Kellerman |
Reducing the risk of human anti-human antibodies through V gene manipulation
|
EP1726647B1
(de)
|
2004-03-19 |
2015-01-07 |
GenomIdea, Inc. |
Gen zur förderung des wachstums von gefässendothelzellen
|
EP1598428A1
(de)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Verfahren und Kits zum Nachweis von erblichen angioedema typ III
|
EP1771205B1
(de)
*
|
2004-06-18 |
2016-10-26 |
Ambrx, Inc. |
Neuartige antigen-bindende polypeptide und ihre verwendungen
|
AU2005327906B2
(en)
*
|
2004-07-21 |
2010-05-13 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
JP5070052B2
(ja)
|
2004-08-17 |
2012-11-07 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
Pde5阻害剤組成物及び心臓疾患を治療する方法
|
NZ554142A
(en)
|
2004-10-06 |
2009-12-24 |
Agri Biotech Pty Ltd |
Antibody production method comprising inserting antigen releasing device into mammal so antibodies are released into its milk
|
AU2005307831A1
(en)
|
2004-11-17 |
2006-05-26 |
Amgen, Inc. |
Fully human monoclonal antibodies to IL-13
|
AU2005319404B2
(en)
|
2004-12-20 |
2011-10-20 |
Amgen Fremont Inc. |
Binding proteins specific for human Matriptase
|
CA2595610C
(en)
|
2004-12-21 |
2013-03-05 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
ATE541934T1
(de)
*
|
2004-12-22 |
2012-02-15 |
Ambrx Inc |
Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
|
US7638491B2
(en)
|
2004-12-22 |
2009-12-29 |
Ambrx, Inc. |
Therapies using non-natural amino acids and polypeptides
|
NZ555386A
(en)
*
|
2004-12-22 |
2011-01-28 |
Ambrx Inc |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
MX2007007591A
(es)
|
2004-12-22 |
2007-07-25 |
Ambrx Inc |
Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
|
EP2284191A3
(de)
|
2004-12-22 |
2011-07-20 |
Ambrx, Inc. |
Prozess zur Herstellung von hGH
|
CA2590164A1
(en)
|
2005-01-26 |
2006-08-03 |
Amgen Fremont Inc. |
Antibodies against interleukin-1 beta
|
CA2609205A1
(en)
*
|
2005-06-03 |
2006-12-14 |
Ambrx, Inc. |
Improved human interferon molecules and their uses
|
GB0511986D0
(en)
*
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
PT2163562E
(pt)
|
2005-06-21 |
2013-12-19 |
Xoma Us Llc |
Anticorpos de ligação a il 1 beta e respectivos fragmentos
|
AU2006272497B2
(en)
|
2005-07-27 |
2012-07-19 |
University Of Florida Research Foundation, Inc. |
Small compounds that correct protein misfolding and uses thereof
|
CN103103238B
(zh)
*
|
2005-08-18 |
2016-08-10 |
Ambrx公司 |
一种在细胞中制造在特定位置处具有所选氨基酸的抗体或抗体片段多肽的方法
|
JP5905184B2
(ja)
|
2005-10-13 |
2016-04-20 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッドHuman Genome Sciences, Inc. |
自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
|
PT1954710E
(pt)
*
|
2005-11-08 |
2011-06-07 |
Ambrx Inc |
Aceleradores para a modificação de aminoácidos nãonaturais e polipeptídeos de aminoácidos não-naturais
|
EP2548583A3
(de)
|
2005-11-10 |
2013-02-27 |
Curagen Corporation |
Verfahren zur behandlung von ovarial- und nierenkarzinom mit antikörpern gegen t-zell-immunglobulin-domänen- und mucin-domänen-1-(tim-1)-antigen
|
WO2007059312A2
(en)
*
|
2005-11-16 |
2007-05-24 |
Ambrx, Inc. |
Methods and compositions comprising non-natural amino acids
|
US20070213264A1
(en)
|
2005-12-02 |
2007-09-13 |
Mingdong Zhou |
Neuregulin variants and methods of screening and using thereof
|
WO2008024128A2
(en)
|
2005-12-05 |
2008-02-28 |
Simon Delagrave |
Loop-variant pdz domains as biotherapeutics, diagnostics and research reagents
|
ATE552853T1
(de)
|
2005-12-13 |
2012-04-15 |
Medimmune Ltd |
Proteine die spezifisch insulin-ähnliche wachstumsfaktoren binden, und deren anwendungen
|
AU2006326404B2
(en)
*
|
2005-12-14 |
2011-11-03 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
AU2005339101B2
(en)
|
2005-12-14 |
2013-01-10 |
Herantis Pharma Plc. |
Novel neurotrophic factor protein and uses thereof
|
NZ569787A
(en)
|
2005-12-15 |
2011-07-29 |
Astrazeneca Ab |
Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer
|
JP5036727B2
(ja)
|
2005-12-22 |
2012-09-26 |
ジェネンテック, インコーポレイテッド |
ヘパリン結合タンパク質の組み換え体産生
|
CA2841386A1
(en)
|
2005-12-30 |
2007-07-12 |
Zensun (Shanghai) Science & Technology Limited |
Extended release of neuregulin for improved cardiac function
|
JP4923625B2
(ja)
*
|
2006-03-01 |
2012-04-25 |
パナソニック株式会社 |
炊飯器
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
EP2049570B1
(de)
|
2006-06-01 |
2016-08-10 |
President and Fellows of Harvard College |
Reinigung von bivalent aktiven antikörpern, mit verwendung von einem nicht-chromatographischen verfahren
|
US9505823B2
(en)
|
2006-08-07 |
2016-11-29 |
TEV A Biopharmaceuticals USA, Inc. |
Albumin-insulin fusion proteins
|
WO2008030613A2
(en)
*
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Hybrid suppressor trna for vertebrate cells
|
AU2007292893B2
(en)
*
|
2006-09-08 |
2012-03-01 |
Ambrx, Inc. |
Suppressor tRNA transcription in vertebrate cells
|
AU2007292903B2
(en)
*
|
2006-09-08 |
2012-03-29 |
Ambrx, Inc. |
Modified human plasma polypeptide or Fc scaffolds and their uses
|
US20080124355A1
(en)
|
2006-09-22 |
2008-05-29 |
David Gordon Bermudes |
Live bacterial vaccines for viral infection prophylaxis or treatment
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
RU2554747C9
(ru)
|
2006-12-20 |
2015-10-20 |
Ксома (Сша) Ллс |
Способы лечения il-1бета-зависимых заболеваний
|
BRPI0809583B1
(pt)
|
2007-03-30 |
2022-02-22 |
Ambrx, Inc |
Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
|
WO2008137471A2
(en)
*
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
US20110065673A1
(en)
|
2007-05-11 |
2011-03-17 |
Bizen Chemical Co., Ltd. |
Novel leukotriene receptor agonist
|
CN101932602B
(zh)
|
2007-06-27 |
2017-05-24 |
新加坡国立大学 |
用于Artemin及相关配体的多肽和多核苷酸,及其使用方法
|
US20090156488A1
(en)
|
2007-09-12 |
2009-06-18 |
Zensun (Shanghai) Science & Technology Limited |
Use of neuregulin for organ preservation
|
EP2040075A1
(de)
|
2007-09-24 |
2009-03-25 |
Julius-Maximilians-Universität Würzburg |
Verbindungen und Marker für oberflächenverstärkte Raman-Streuung
|
AR068566A1
(es)
|
2007-09-26 |
2009-11-18 |
Amgen Inc |
Proteinas fijadoras de antigeno de factor de crecimiento del tipo factor de crecimiento epidermico fijador de heparina
|
US8946148B2
(en)
*
|
2007-11-20 |
2015-02-03 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
AU2008343085B2
(en)
|
2007-12-20 |
2015-03-12 |
Xoma (Us) Llc |
Methods for the treatment of gout
|
CN101939443B
(zh)
|
2008-02-08 |
2014-01-29 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
FI20080326A0
(fi)
|
2008-04-30 |
2008-04-30 |
Licentia Oy |
Neurotroofinen tekijä MANF ja sen käytöt
|
HUE043090T2
(hu)
|
2008-06-09 |
2019-08-28 |
Univ Muenchen Ludwig Maximilians |
Gyógyszerek fehérjék aggregálódásának gátlására olyan betegségeknél, amelyek fehérje-aggregálódással és/vagy neurodegeneratív megbetegedésekkel függnek össze
|
UA118536C2
(uk)
|
2008-07-23 |
2019-02-11 |
Амбркс, Інк. |
Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
|
EP2316030B1
(de)
|
2008-07-25 |
2019-08-21 |
Wagner, Richard W. |
Proteinscreeningverfahren
|
BRPI0913476A2
(pt)
|
2008-09-10 |
2015-12-01 |
Genentech Inc |
"usos de um antagonista tspan12 e usos de um antagonista de norrin"
|
EP2927244A1
(de)
|
2008-09-19 |
2015-10-07 |
MedImmune, LLC |
Gegen DLL4 gerichtete Antikörper und ihre Verwendung
|
BRPI0919403A2
(pt)
|
2008-09-26 |
2017-09-26 |
Ambrx Inc |
polipeptídeos modificados de eritropoetina animal e seus usos
|
ES2660000T3
(es)
|
2008-09-26 |
2018-03-20 |
Ambrx, Inc. |
Vacunas y microorganismos dependientes de la replicación de aminoácidos no naturales
|
US20120087870A1
(en)
|
2008-12-19 |
2012-04-12 |
Hentges Francois |
Novel caviidae allergens and uses thereof
|
EP2367564A1
(de)
|
2008-12-22 |
2011-09-28 |
Universität Regensburg |
Norrin bei der behandlung von erkrankungen im zusammenhang mit erhöhter tgf-beta-aktivität
|
EP2379595A2
(de)
|
2008-12-23 |
2011-10-26 |
AstraZeneca AB |
Gegen a5b1 gerichtete gezielt bindende mittel und anwendungen davon
|
EP2390261A4
(de)
|
2009-01-20 |
2012-11-14 |
Hanall Biopharma Co Ltd |
Modifiziertes menschliches thrombopoietin-polypeptid-fragment und verfahren zu seiner herstellung
|
US8241623B1
(en)
|
2009-02-09 |
2012-08-14 |
David Bermudes |
Protease sensitivity expression system
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
CN102369211B
(zh)
|
2009-02-13 |
2015-04-29 |
诺华股份有限公司 |
编码非核糖体肽合酶的生物合成簇的核酸分子及其用途
|
US8283162B2
(en)
*
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
EP2260857A1
(de)
|
2009-06-11 |
2010-12-15 |
Alfact Innovation |
Neuartige Anwendungen von HIP/PAP und Derivate davon
|
IN2012DN00352A
(de)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
EP2305285A1
(de)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Mittel und Verfahren zur Behandlung von ischämischen Erkrankungen
|
EP2305810A1
(de)
|
2009-10-02 |
2011-04-06 |
Technische Universität München |
miRNAs in der Behandlung von Fibrose
|
WO2011046457A1
(en)
|
2009-10-16 |
2011-04-21 |
Auckland Uniservices Limited |
Anti-neoplastic uses of artemin antagonists
|
WO2011056650A2
(en)
|
2009-10-27 |
2011-05-12 |
Michael Zasloff |
Methods and compositions for treating and preventing viral infections
|
KR101790767B1
(ko)
|
2009-11-24 |
2017-10-26 |
메디뮨 리미티드 |
B7―h1에 대한 표적화된 결합 물질
|
US8623416B2
(en)
|
2009-11-25 |
2014-01-07 |
Michael Zasloff |
Formulations comprising aminosterols
|
WO2011087808A1
(en)
|
2009-12-21 |
2011-07-21 |
Ambrx, Inc. |
Modified bovine somatotropin polypeptides and their uses
|
MX2012006980A
(es)
|
2009-12-21 |
2012-07-17 |
Ambrx Inc |
Polipeptidos de somatotropina porcina modificados y sus usos.
|
EP2525792A1
(de)
|
2010-01-19 |
2012-11-28 |
Medizinische Universität Wien |
Pharmazeutische zusammensetzungen mit lignanen und ihren derivaten zur medizinischen verwaltung von angiogenese und hypovaskularität
|
CA2788021A1
(en)
|
2010-01-27 |
2011-08-04 |
Children's Medical Center Corporation |
Pro-angiogenic fragments of prominin-1 and uses thereof
|
US9597379B1
(en)
|
2010-02-09 |
2017-03-21 |
David Gordon Bermudes |
Protease inhibitor combination with therapeutic proteins including antibodies
|
US8771669B1
(en)
|
2010-02-09 |
2014-07-08 |
David Gordon Bermudes |
Immunization and/or treatment of parasites and infectious agents by live bacteria
|
US8524220B1
(en)
|
2010-02-09 |
2013-09-03 |
David Gordon Bermudes |
Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
|
WO2011131626A1
(en)
|
2010-04-19 |
2011-10-27 |
Medizinische Universität Innsbruck |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
EP2566964B1
(de)
|
2010-05-07 |
2016-10-19 |
Centre National De La Recherche Scientifique |
Ucp1 (thermogenin) - induzierende mittel zur verwendung in der behandlung von erkrankungen der energie-homöostase
|
RU2012157399A
(ru)
|
2010-06-18 |
2014-07-27 |
КсайберСайенс ГмбХ |
Пептиды в качестве активных агентов для стабилизации биологических барьеров
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
BR112013003522B1
(pt)
|
2010-08-17 |
2021-05-25 |
Ambrx, Inc. |
polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
ES2641880T3
(es)
|
2011-01-27 |
2017-11-14 |
Neuren Pharmaceuticals Limited |
Tratamiento de trastornos del espectro autista usando ácido glicil-L-2-metilprolil-L-glutámico
|
EP2683368A1
(de)
|
2011-03-10 |
2014-01-15 |
F.Hoffmann-La Roche Ag |
Behandlung von erkrankungen mit veränderter gefässbarrierefunktion
|
EA032666B1
(ru)
|
2011-06-14 |
2019-06-28 |
Бикам Фармасьютикалз, Инк. |
Опсинсвязывающие лиганды и способы их применения
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
WO2013024144A1
(en)
|
2011-08-16 |
2013-02-21 |
Evotec (München) Gmbh |
Markers for susceptibility to an inhibitor of an src-family kinase
|
WO2013053076A1
(en)
|
2011-10-10 |
2013-04-18 |
Zensun (Shanghai)Science & Technology Limited |
Compositions and methods for treating heart failure
|
BR112014011912A2
(pt)
|
2011-11-16 |
2017-05-16 |
Amgen Inc |
método para o tratamento de um mamífero que tem um tumor
|
US9353063B2
(en)
|
2011-11-30 |
2016-05-31 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
EP2601941A1
(de)
|
2011-12-06 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Verbindungen auf beta-O/S/N-Fettsäurebasis als Antibakterium- und Antiprotozoenmittel
|
EP2788500A1
(de)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identifizierung von non-respondern auf her2-inhibitoren
|
US20150017157A1
(en)
|
2011-12-19 |
2015-01-15 |
Xoma (Us) Llc |
Methods for treating acne
|
US20150011431A1
(en)
|
2012-01-09 |
2015-01-08 |
The Scripps Research Institute |
Humanized antibodies
|
US20140050720A1
(en)
|
2012-01-09 |
2014-02-20 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
EP2626066A1
(de)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Kombinationstherapie mit selektiven VEGFR-2-Inhibitoren und MEK-Inhibitoren
|
EP2666775A1
(de)
|
2012-05-21 |
2013-11-27 |
Domain Therapeutics |
Substituierte Pyrazolochinazolinone und Pyrrolochinazolinone als allosterische Modulatoren von metabotropen Glutamatrezeptoren der Gruppe II
|
CA2877441A1
(en)
|
2012-07-02 |
2014-01-09 |
Medizinische Universitat Wien |
Complement split product c4d for the treatment of inflammatory conditions
|
EP2687225A1
(de)
|
2012-07-19 |
2014-01-22 |
Alfact Innovation |
HIP/PAP-Protein und Derivate davon zur Verwendung bei der Behandlung von Krebs
|
EP2695950A1
(de)
|
2012-08-10 |
2014-02-12 |
Blackfield AG |
Marker für die Empfindlichkeit auf einen Hemmer des Fibroblastenwachstumsrezeptors
|
JP2015526471A
(ja)
|
2012-08-21 |
2015-09-10 |
ジェネシス リサーチ インスティチュート |
アントラサイクリン誘発性心毒性を治療または予防するための組成物および方法
|
KR102291355B1
(ko)
|
2012-11-30 |
2021-08-19 |
에프. 호프만-라 로슈 아게 |
Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
|
US9593339B1
(en)
|
2013-02-14 |
2017-03-14 |
David Gordon Bermudes |
Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
|
EP3461909A1
(de)
|
2013-05-21 |
2019-04-03 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Spezifische isoformen von gata6 und nkx2-1 als neue marker zur diagnose und für therapieansätze bei krebs und als ziele zur behandlung von krebs
|
CN105611955A
(zh)
|
2013-05-22 |
2016-05-25 |
上海泽生科技开发有限公司 |
缓释纽兰格林治疗心力衰竭
|
WO2014191630A2
(en)
|
2013-05-28 |
2014-12-04 |
Helsingin Yliopisto |
Non-human animal model encoding a non-functional manf gene
|
EP2810648A1
(de)
|
2013-06-04 |
2014-12-10 |
Daniel Rauh |
Domänen-Domänen-Interaktionstargeting zur Identifizierung von Kinasemodulatoren
|
EP2835135A3
(de)
|
2013-06-19 |
2015-06-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
Mittel und Verfahren zur Behandlung einer Pseudomonas-Infektion
|
WO2014207213A1
(en)
|
2013-06-28 |
2014-12-31 |
Medizinische Universität Innsbruck |
Novel inhibitors of protein kinase c epsilon signaling
|
CA2918370A1
(en)
|
2013-07-18 |
2015-01-22 |
Fabrus, Inc. |
Humanized antibodies with ultralong complementarity determining regions
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
WO2015022326A1
(en)
|
2013-08-12 |
2015-02-19 |
Xiber Science Gmbh |
Peptides as active agents for treating primary graft dysfunction
|
US10286078B2
(en)
|
2013-09-13 |
2019-05-14 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
DK3494985T3
(da)
|
2013-09-16 |
2021-04-19 |
Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh |
Vaccinesammensætning omfattende mutant calreticulin
|
US20150238631A1
(en)
|
2013-10-15 |
2015-08-27 |
The California Institute For Biomedical Research |
Chimeric antigen receptor t cell switches and uses thereof
|
CA2927543C
(en)
|
2013-10-15 |
2021-07-20 |
The California Institute For Biomedical Research |
Peptidic chimeric antigen receptor t cell switches and uses thereof
|
GB201319374D0
(en)
|
2013-11-01 |
2013-12-18 |
Univ Nottingham |
Glycans as functional cancer targets abd antibodies thereto
|
AU2014364589B2
(en)
|
2013-12-18 |
2020-02-27 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
EP3104873B1
(de)
|
2014-02-13 |
2019-09-04 |
Technische Universität München |
Fgf-8 zur verwendung zur behandlung von erkrankungen oder störungen der energiehomöostase
|
CA2888068A1
(en)
|
2014-04-15 |
2015-10-15 |
The Hospital For Sick Children |
Cationic antimicrobial peptides
|
EP3143143A1
(de)
|
2014-05-15 |
2017-03-22 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Antagonisten von slc38a9 und deren verwendung in der therapie
|
EP2947460A1
(de)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalisierte Therapie von Entzündungen um Zusammenhang mit Krebs mithilfe von Verfahren zur Bestimmung der Empfänglichkeit auf die Behandlung mit EGFR-Hemmern/-Antagonisten
|
EA201790434A1
(ru)
|
2014-08-22 |
2017-07-31 |
Окленд Юнисервисиз Лимитед |
Модуляторы каналов
|
EP3000814A1
(de)
|
2014-09-26 |
2016-03-30 |
Domain Therapeutics |
Substituierte Pyrazolochinazolinone und Pyrrolochinazolinone als allosterische Modulatoren von metabotropen Glutamatrezeptoren der Gruppe II
|
US9434778B2
(en)
|
2014-10-24 |
2016-09-06 |
Bristol-Myers Squibb Company |
Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
|
WO2016079321A1
(en)
|
2014-11-20 |
2016-05-26 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of setdb2 for use in the therapy of infectious diseases
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
KR20170138410A
(ko)
|
2015-02-23 |
2017-12-15 |
시걸 테라퓨틱스 에스에이에스 |
비-천연 세마포린 3 및 이의 의학적 용도
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
EP3283113A4
(de)
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimierte pne-basierte chimäre t-zell-rezeptor-schalter und verwendungen davon
|
WO2016170102A1
(en)
|
2015-04-22 |
2016-10-27 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
EP3310376A4
(de)
|
2015-06-17 |
2019-01-23 |
The California Institute for Biomedical Research |
Modifizierte therapeutische mittel und zusammensetzungen daraus
|
WO2017007955A1
(en)
|
2015-07-07 |
2017-01-12 |
The Research Foundation For The State University Of New York |
Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
|
BR112018009550A2
(pt)
|
2015-11-13 |
2018-11-06 |
Mavalon Therapeutics Ltd |
derivados de 1,4-benzodiazepinona tricíclica substituída como moduladores alostéricos de receptores de glutamato metabotrópico de grupo ii
|
AU2016367306B2
(en)
|
2015-12-09 |
2021-04-22 |
Medizinische Universität Wien |
Monomaleimide-functionalized platinum compounds for cancer therapy
|
AU2017207867A1
(en)
|
2016-01-15 |
2018-08-09 |
Universität Hamburg |
Flavonoide-type compounds bearing an O-rhamnosyl residue
|
US10702518B2
(en)
|
2016-02-15 |
2020-07-07 |
CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH |
TAF1 inhibitors for the therapy of cancer
|
EP3216458A1
(de)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modifizierter vaskulärer endothelialen wachstumsfaktor a (vegf-a) und dessen medizinische verwendung
|
ES2957548T3
(es)
|
2016-04-15 |
2024-01-22 |
Univ Oxford Innovation Ltd |
Moduladores del receptor de adenosina para el tratamiento de los trastornos del ritmo circadiano
|
US20200030295A1
(en)
|
2016-08-02 |
2020-01-30 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Heterocyclic diamidines
|
KR102613430B1
(ko)
|
2016-10-19 |
2023-12-18 |
더 스크립스 리서치 인스티튜트 |
인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
|
CN110225755A
(zh)
|
2016-11-14 |
2019-09-10 |
分子医学研究中心责任有限公司 |
Brd4抑制剂和抗叶酸剂的组合用于治疗癌症
|
MA46937A
(fr)
|
2016-11-30 |
2019-10-09 |
Oncotyrol Center For Personalized Cancer Medicine Gmbh |
3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones en tant qu'inhibiteurs de kinases dépendantes des cyclines
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
TW201837051A
(zh)
|
2017-02-08 |
2018-10-16 |
美商必治妥美雅史谷比公司 |
包含藥物動力學增強劑之經修飾之鬆弛素(relaxin)多肽及其用途
|
CA3062749A1
(en)
|
2017-05-12 |
2018-11-15 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. |
Compounds for use in the treatment or prevention of melanoma
|
WO2018206820A1
(en)
|
2017-05-12 |
2018-11-15 |
Mavalon Therapeutics Limited |
Substituted heterocyclic compounds as allosteric modulators of group ii metabotropic glutamate receptors
|
WO2019018691A1
(en)
|
2017-07-19 |
2019-01-24 |
Auckland Uniservices Limited |
MODULATION OF CYTOKINE
|
FR3072880A1
(fr)
*
|
2017-10-30 |
2019-05-03 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Formulation liposomale et son utilisation en therapie anti-tumorale
|
US11066438B2
(en)
|
2017-10-30 |
2021-07-20 |
Enterin, Inc. |
Squalamine solid forms and methods of making the same
|
WO2019110139A1
(en)
|
2017-12-05 |
2019-06-13 |
Eth Zurich |
New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
|
US20210163406A1
(en)
|
2018-04-06 |
2021-06-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
|
US20210022978A1
(en)
|
2018-04-06 |
2021-01-28 |
Zilentin AG |
Bumetanide derivatives for the therapy of hyperhidrosis
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
JP2021535140A
(ja)
|
2018-08-28 |
2021-12-16 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
抗cd3抗体葉酸生物複合体およびその使用
|
AU2019337610A1
(en)
|
2018-09-11 |
2021-05-06 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
EP3867265A1
(de)
|
2018-10-19 |
2021-08-25 |
Ambrx, Inc. |
Interleukin-10 -polypeptid-konjugate, dimere davon und ihre verwendungen
|
WO2020127200A1
(en)
|
2018-12-17 |
2020-06-25 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
|
WO2020168017A1
(en)
|
2019-02-12 |
2020-08-20 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
CA3148591A1
(en)
|
2019-07-26 |
2021-02-04 |
Amgen Inc. |
Anti-il13 antigen binding proteins
|
AU2020328507A1
(en)
|
2019-08-12 |
2022-03-17 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
|
KR20220079597A
(ko)
|
2019-10-02 |
2022-06-13 |
톨레모 테라퓨틱스 아게 |
헤테로사이클릭 유도체, 약학 조성물 및 암의 치료 또는 개선에서 그들의 용도
|
WO2021064141A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
|
AU2020366135A1
(en)
|
2019-10-16 |
2022-06-02 |
Proxygen Gmbh |
Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
AU2020371784A1
(en)
|
2019-10-24 |
2022-06-02 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
CN114728927A
(zh)
|
2019-11-19 |
2022-07-08 |
莫达戈有限公司 |
用于诊断、治疗和预防与α-突触核蛋白的聚集相关的疾病的新颖化合物
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
CA3174114A1
(en)
|
2020-03-11 |
2021-09-16 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
CA3184062A1
(en)
|
2020-06-25 |
2021-12-30 |
Stefanie Fluckiger-Mangual |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
|
EP3939578A1
(de)
|
2020-07-13 |
2022-01-19 |
Novaremed Ltd. |
Verbindungen zur behandlung oder vorbeugung einer infektion, die aus einer coronavirus- und/oder einer coronavirusinduzierten erkrankung resultiert
|
US20230302150A1
(en)
|
2020-08-20 |
2023-09-28 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
EP3964497A1
(de)
|
2020-09-04 |
2022-03-09 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Substituierte vicinale diaminverbindungen und deren verwendung zur behandlung, linderung oder vorbeugung von schmerzen
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
CA3194868A1
(en)
|
2020-10-16 |
2022-04-21 |
Georg Winter |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
CN117321076A
(zh)
|
2021-02-19 |
2023-12-29 |
美国卫生及公众服务部代表 |
中和SARS-CoV-2的单结构域抗体
|
IL307282A
(en)
|
2021-04-03 |
2023-11-01 |
Ambrx Inc |
Antidote conjugates against HER2 and their applications
|
AU2022253869A1
(en)
|
2021-04-07 |
2023-10-05 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
AU2022264339A1
(en)
|
2021-04-28 |
2023-11-09 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
BR112023022474A2
(pt)
|
2021-05-14 |
2024-01-09 |
Claris Biotherapeutics Inc |
Composições de fator de crescimento para o tratamento de doença ocular
|
US20230364031A1
(en)
|
2022-04-19 |
2023-11-16 |
Garth Cooper |
Treatment of brain copper disorders
|
WO2023203174A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|